Cediranib

ASCO: Olaparib and cediranib combo promising for recurrent ovarian cancer
June 05, 2014For women with recurrent platinum-sensitive ovarian cancer, the combination of the PARP inhibitor olaparib and the anti-angiogenesis drug cediranib is more effective than olaparib alone.
Cediranib improves survival in recurrent ovarian cancer
October 21, 2013Women with ovarian cancer that has recurred after chemotherapy survived longer after treatment with cediranib, a biological therapy, according to research.
Sign Up for Free e-newsletters
ONA Articles
- Physical Inactivity Linked With Increased Risk of Hodgkin, Non-Hodgkin Lymphoma
- Challenges for Young Adult Couples Facing a Cancer Diagnosis
- Redefining Prognosis for Hematologic Cancers in Older Adults by Age
- Progression-Free Survival Extended With PANEX Protocol in R/R Multiple Myeloma
- Following ACS Guidelines Shown to Improve Outcomes for Colon Cancer Survivors
- Letter-Writing Project Communicates Care Wishes to Healthcare Team, Family
- Pivot Nurse Improves Patients' Navigation Through Lung Cancer Care
- Long-term Carfilzomib May Be Safe, Effective In Relapsed Multiple Myeloma
- Palliative Sedation a Valid Option for Refractory Symptoms in End-stage Cancer
- Testicular Cancer Treatment May Increase Risk for Heart Disease in Survivors
- Chronic Opioid Use Observed in More Than 50% of Oropharynx Cancer Cases
- Spotlight on Triptorelin in the Treatment of Premenopausal Women with Early-Stage Breast Cancer
- Redefining Prognosis for Hematologic Cancers in Older Adults by Age
- Outcomes for Elderly With Hematologic Cancers Effected by Cognitive Impairments
- Evolving Role of Radiation Therapy in the Treatment of Mesothelioma
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
Bone Cancer | Regimens | Drugs |
Brain Cancer | Regimens | Drugs |
Breast Cancer | Regimens | Drugs |
Endocrine Cancer | Regimens | Drugs |
Gastrointestinal Cancer | Regimens | Drugs |
Genitourinary Cancer | Regimens | Drugs |
Gynecologic Cancer | Regimens | Drugs |
Head and Neck Cancer | Regimens | Drugs |
Hematologic Cancer | Regimens | Drugs |
Lung Cancer | Regimens | Drugs |
Other Cancers | Regimens | |
Rare Cancers | Regimens | |
Skin Cancer | Regimens | Drugs |